Vosaroxin for acute myeloid leukemia

LAUR Repository

Show simple item record

dc.contributor.author El-Amm, Joelle
dc.contributor.author Tabbara, Imad A.
dc.date.accessioned 2017-09-25T08:30:27Z
dc.date.available 2017-09-25T08:30:27Z
dc.date.copyright 2014 en_US
dc.identifier.issn 2041-6806 en_US
dc.identifier.uri http://hdl.handle.net/10725/6262
dc.description.abstract The treatment of acute myeloid leukemia (AML) in adults has not significantly changed in the past five decades. Despite the availability of effective induction chemotherapy, most patients eventually relapse. Relapsed or refractory AML, and AML in patients 60 years of age and older are particularly difficult to treat and have poor prognosis hence the need for novel therapies. Vosaroxin is a novel first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. Vosaroxin was shown in preclinical studies to be a potent antileukemia agent with unique features that overcome common mechanisms of resistance to standard therapy. Vosaroxin as single agent or in combination with cytarabine showed promising tolerability and activity in Phase I and II studies. The combination of vosaroxin and cytarabine is currently being studied in the Phase III VALOR trial that will define the role of vosaroxin in first relapsed or refractory AML. This review summarizes the preclinical and clinical studies of vosaroxin in AML. en_US
dc.language.iso en en_US
dc.title Vosaroxin for acute myeloid leukemia en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201603787 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Clinical investigation en_US
dc.journal.volume 4 en_US
dc.journal.issue 2 en_US
dc.article.pages 147-152 en_US
dc.keywords Acute myeloid leukemia en_US
dc.keywords Quinolones en_US
dc.keywords Voreloxin en_US
dc.keywords Vosaroxin en_US
dc.identifier.doi http://dx.doi.org/10.4155/CLI.13.126 en_US
dc.identifier.ctation El-Amm, J., & Tabbara, I. A. (2014). Vosaroxin for acute myeloid leukemia. Clinical Investigation, 4(2), 147-152. en_US
dc.author.email joelle.elamm@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://www.openaccessjournals.com/articles/vosaroxin-for-acute-myeloid-leukemia.pdf en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account